125 Article(s)
Pub. Date
#Total Relationship(s)
1 1521904 Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992 Mar 1
2 1560570 [Effect of nafamostat mesilate on the renin-aldosterone system]. Masui 1992 Mar 1
3 1768503 Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991 Oct-Dec 1
4 1861238 Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn. J Pharmacobiodyn 1991 Jan 1
5 1989498 The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175. Arch Biochem Biophys 1991 Jan 1
6 2050602 Consumption coagulopathy associated with left atrial thrombosis. Hematol Pathol 1991 2
7 2128896 Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Pharm Res 1990 Dec 3
8 2435641 [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro]. Nihon Yakurigaku Zasshi 1986 Dec 3
9 2739065 [The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock]. Masui 1989 Mar 2
10 6086386 Detection of intermediary Clr with complete active site, using a synthetic proteinase inhibitor. FEBS Lett 1984 Jul 9 2
11 6215361 Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 1982 4
12 6618346 [Immunopharmacological actions of 6-amidino-2-naphthyl-4-guanidinobenzoate (FUT-175). 1. Effect of FUT-175 on immune response and host defense in mice]. Nihon Yakurigaku Zasshi 1983 Jun 1
13 7620820 Inhibitory effect of FUT-175 on the production of interleukin 8 and polymorphonuclear leukocyte elastase. Res Commun Mol Pathol Pharmacol 1995 Mar 2
14 7763192 Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis. Artif Organs 1995 Feb 1
15 7816751 Effect of epidermal growth factor on Cu, Zn-superoxide dismutase expression in cultured fibroblasts from rat skin. Pharm Res 1994 Sep 1
16 7836734 Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994 Oct 2
17 7959424 [Effects of E3123 on pancreatic injury in the isolated, perfused rat pancreas and in a pancreatic slice]. Nihon Yakurigaku Zasshi 1994 Oct 2
18 8029816 Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb Res 1994 Apr 15 1
19 8312873 Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats. Biol Pharm Bull 1993 Nov 4
20 9032217 Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 1997 Feb 1
21 9127328 Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. Nephron 1997 3
22 9128326 Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy. Am J Gastroenterol 1997 Apr 1
23 10066865 Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. Stroke 1999 Mar 1
24 10430784 Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 1999 Aug 5
25 10440571 FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol 1999 Jan 4
26 10655909 A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth 1999 Sep 1
27 10954057 Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci 2000 2
28 11294265 Extracorporeal membrane oxygenation for newborns with gastric rupture. Pediatr Surg Int 2001 1
29 11958287 Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Res Commun Mol Pathol Pharmacol 2000 Nov-Dec 1
30 12203894 Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits. Proteomics 2002 Aug 1
31 12506133 Inhibition of prostasin secretion by serine protease inhibitors in the kidney. J Am Soc Nephrol 2003 Jan 2
32 12592100 Induction of IkappaB-kinase by cholecystokinin is mediated by trypsinogen activation in rat pancreatic lobules. Digestion 2002 1
33 12642398 A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br J Pharmacol 2003 Mar 4
34 12744489 Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. Shock 2003 May 1
35 12890431 Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol 2003 Sep 5
36 15655299 Physiology and pathophysiology of proteinase-activated receptors (PARs): role of tryptase/PAR-2 in vascular endothelial barrier function. J Pharmacol Sci 2005 Jan 1
37 15894839 A serine protease inhibitor, nafamostat mesilate, suppresses aldosterone secretions in vivo. Hypertens Res 2004 Dec 1
38 16093612 Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells. J Pharmacol Sci 2005 Aug 6
39 16260585 Involvement of neutrophil recruitment and protease-activated receptor 2 activation in the induction of IL-18 in mice. J Leukoc Biol 2005 Nov 1
40 16359660 Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006 Jan 13 4
41 16552341 Intracellular activation of trypsinogen in rat pancreatic acini after supramaximal secretagogue stimulation: cysteine protease and serine protease activity. Pancreas 2006 Mar 1
42 16612309 Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. J Trauma 2006 Apr 1
43 16702735 Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 2006 Apr 1
44 16801094 Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets 1999 Jul 2
45 16815145 Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006 Jul 1
46 17414427 Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7. Shock 2007 Apr 1
47 17458645 Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J Anesth 2007 1
48 17624024 Nafamostat is hydrolysed by human liver cytosolic long-chain acyl-CoA hydrolase. Xenobiotica 2007 Mar 1
49 18602161 Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol 2008 Aug 2
50 19008643 Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. J Pharmacol Sci 2008 Nov 3